Surgery Partners (SGRY) Financials

$14.48 +0.17 (+1.19%)

Closing price 04:00 PM Eastern

Extended Trading

$14.48 -0.01 (-0.03%)

As of 06:39 PM Eastern

Annual Income Statements for Surgery Partners

This table shows Surgery Partners' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-66	1.43	9.45	-238	-111	-156	-81	-55	-12	-168	-78
Consolidated Net Income / (Loss)	-27	73	85	-96	45	1.30	71	87	135	13	99
Net Income / (Loss) Continuing Operations	-27	73	85	-96	45	1.30	71	87	135	13	99
Total Pre-Tax Income	-11	-76	92	-69	55	-19	81	110	135	147	117
Total Operating Income	51	145	196	78	236	183	302	345	328	349	390
Total Gross Profit	149	291	324	497	774	771	944	1,083	1,029	1,192	2,338
Total Revenue	403	960	1,145	1,772	1,831	1,860	2,225	2,539	2,743	3,114	3,309
Operating Revenue	403	960	1,145	1,772	1,831	1,860	2,225	2,539	2,743	3,114	3,309
Total Cost of Revenue	254	669	821	1,275	1,058	1,089	1,281	1,456	1,714	1,922	971
Operating Cost of Revenue	254	669	821	1,275	1,058	1,089	1,281	1,456	1,714	1,922	971
Total Operating Expenses	98	146	128	419	538	588	642	738	701	843	1,948
Selling, General & Admin Expense	31	56	60	94	353	401	466	528	418	496	1,603
Depreciation Expense	15	35	40	67	77	95	99	115	118	153	176
Other Operating Expenses / (Income)	28	40	34	110	83	36	53	96	101	116	97
Restructuring Charge	22	18	8.74	32	19	23	40	48	62	100	74
Other Special Charges / (Income)	1.80	-2.62	-14	42	-1.20	-0.50	-16	-48	3.10	-21	-1.40
Total Other Income / (Expense), net	-62	-221	-104	-147	-181	-202	-221	-235	-193	-202	-273
Interest & Investment Income	-62	-101	-101	-147	-179	-202	-221	-235	-193	-202	-273
Income Tax Expense	16	-149	7.10	26	9.50	-20	11	23	-0.30	135	18
Net Income / (Loss) Attributable to Noncontrolling Interest	39	71	76	143	156	157	142	142	147	181	177
Basic Earnings per Share	($2.04)	$0.04	$0.20	($4.96)	($2.29)	($3.19)	($1.12)	($0.59)	($0.09)	($1.33)	($0.61)
Weighted Average Basic Shares Outstanding	32.30M	36.07M	48.02M	48.03M	48.28M	48.78M	72.43M	91.95M	125.61M	126.12M	127.21M
Diluted Earnings per Share	($2.04)	$0.04	$0.20	($4.96)	($2.29)	($3.19)	($1.12)	($0.59)	($0.09)	($1.33)	($0.61)
Weighted Average Diluted Shares Outstanding	32.30M	37.46M	48.19M	48.03M	48.28M	48.78M	72.43M	91.95M	125.61M	126.12M	127.21M
Weighted Average Basic & Diluted Shares Outstanding	-	35.70M	48.63M	48.03M	48.28M	48.78M	89.36M	126.03M	126.61M	127.61M	129.42M

This table shows Surgery Partners' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-4.90	-1.00	-12	-16	-32	-109	-38	-2.50	-23	-15	-36
Consolidated Net Income / (Loss)	30	47	24	28	6.40	-47	-0.30	45	25	29	-2.10
Net Income / (Loss) Continuing Operations	30	47	24	28	6.40	-47	-0.30	45	25	29	-2.10
Total Pre-Tax Income	33	53	29	33	11	74	-0.30	44	31	43	-3.30
Total Operating Income	83	101	76	85	61	127	62	112	106	110	66
Total Gross Profit	479	768	259	294	292	97	278	376	579	1,061	564
Total Revenue	674	735	717	762	770	864	776	826	822	885	811
Operating Revenue	674	735	717	762	770	864	776	826	822	885	811
Total Cost of Revenue	195	-33	458	468	478	767	498	450	243	-176	247
Operating Cost of Revenue	195	-33	458	468	478	767	498	450	243	-176	247
Total Operating Expenses	397	667	183	209	232	-30	216	264	473	951	498
Selling, General & Admin Expense	329	575	116	133	120	-123	131	194	384	850	420
Depreciation Expense	29	31	34	35	50	34	36	40	40	60	39
Other Operating Expenses / (Income)	23	38	20	28	33	34	22	14	33	28	23
Restructuring Charge	13	24	17	19	29	34	25	18	13	19	16
Other Special Charges / (Income)	2.40	-1.80	-3.80	-6.00	-1.70	-9.30	2.20	-2.10	3.40	-4.90	0.80
Total Other Income / (Expense), net	-50	-49	-47	-52	-50	-53	-62	-68	-75	-68	-69
Interest & Investment Income	-50	-49	-47	-52	-50	-53	-62	-68	-75	-68	-69
Income Tax Expense	3.10	6.00	4.40	4.90	4.50	121	0.00	-1.10	5.50	14	-1.20
Net Income / (Loss) Attributable to Noncontrolling Interest	35	48	37	44	38	62	37	47	48	44	34
Basic Earnings per Share	($0.04)	-	($0.10)	($0.12)	($0.25)	($0.86)	($0.30)	($0.02)	($0.18)	($0.11)	($0.28)
Weighted Average Basic Shares Outstanding	125.75M	125.61M	125.97M	126.13M	126.17M	126.12M	126.60M	126.98M	127.21M	127.21M	128.37M
Diluted Earnings per Share	($0.04)	-	($0.10)	($0.12)	($0.25)	($0.86)	($0.30)	($0.02)	($0.18)	($0.11)	($0.28)
Weighted Average Diluted Shares Outstanding	125.75M	125.61M	125.97M	126.13M	126.17M	126.12M	126.60M	126.98M	127.21M	127.21M	128.37M
Weighted Average Basic & Diluted Shares Outstanding	126.49M	126.61M	127.09M	127.12M	127.11M	127.61M	128.16M	128.21M	129.34M	129.42M	130.79M

This table details how cash moves in and out of Surgery Partners' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	62	-17	12	9.40	-92	225	72	-107	-87	74	-30
Net Cash From Operating Activities	22	84	125	145	130	247	87	159	294	300	274
Net Cash From Continuing Operating Activities	22	84	125	145	130	247	87	159	294	300	274
Net Income / (Loss) Continuing Operations	-27	73	85	-96	45	1.30	71	87	135	13	99
Consolidated Net Income / (Loss)	-27	73	85	-96	45	1.30	71	87	135	13	99
Depreciation Expense	15	35	40	67	77	95	99	115	118	153	176
Non-Cash Adjustments To Reconcile Net Income	36	165	37	114	68	93	-16	96	106	122	93
Changes in Operating Assets and Liabilities, net	-5.65	-194	-37	59	-60	58	-67	-139	-65	13	-94
Net Cash From Investing Activities	-271	-135	-185	-129	-85	-88	-332	-308	-226	-489	-247
Net Cash From Continuing Investing Activities	-271	-135	-185	-129	-85	-88	-332	-308	-226	-489	-247
Purchase of Property, Plant & Equipment	-7.74	-33	-39	-40	-74	-43	-58	-81	-89	-90	-79
Acquisitions	-263	-113	-146	-107	-14	-105	-286	-242	-130	-381	-175
Sale of Property, Plant & Equipment	-	-	-	19	18	59	6.00	13	26	2.60	47
Divestitures	0.00	11	0.77	-	-	0.00	5.40	13	1.40	4.60	1.50
Other Investing Activities, net	-	-	0.00	-1.50	-0.20	0.60	0.30	-12	-34	-25	-41
Net Cash From Financing Activities	311	33	71	-6.30	-136	67	316	42	-155	262	-57
Net Cash From Continuing Financing Activities	311	33	71	-6.30	-136	67	316	42	-155	262	-57
Repayment of Debt	-1,035	-336	-493	-168	-518	-226	-373	-883	-844	-1,307	-1,035
Payment of Dividends	-128	-82	-86	-119	-124	-137	-165	-150	-138	-161	-225
Issuance of Debt	1,477	196	651	283	507	429	299	218	827	1,730	1,203
Cash Interest Paid	50	97	79	145	180	204	194	219	170	200	257
Cash Income Taxes Paid	0.68	1.09	0.66	2.20	1.60	1.70	1.50	1.80	1.40	1.60	1.20

This table details how cash moves in and out of Surgery Partners' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	59	-40	-11	28	8.30	48	-40	21	-47	37	-58
Net Cash From Operating Activities	105	63	41	83	65	111	6.00	81	84	103	12
Net Cash From Continuing Operating Activities	105	63	41	83	65	111	6.00	81	84	103	12
Net Income / (Loss) Continuing Operations	30	47	24	28	6.40	-47	-0.30	45	25	29	-2.10
Consolidated Net Income / (Loss)	30	47	24	28	6.40	-47	-0.30	45	25	29	-2.10
Depreciation Expense	29	31	34	35	50	34	36	40	40	60	39
Non-Cash Adjustments To Reconcile Net Income	24	41	18	36	34	34	27	14	32	20	26
Changes in Operating Assets and Liabilities, net	23	-57	-35	-16	-26	90	-57	-18	-13	-5.00	-51
Net Cash From Investing Activities	-26	-58	-83	-244	-50	-112	-76	2.10	-46	-126	-13
Net Cash From Continuing Investing Activities	-26	-58	-83	-244	-50	-112	-76	2.10	-46	-126	-13
Purchase of Property, Plant & Equipment	-19	-20	-21	-27	-20	-22	-23	-23	-20	-13	-16
Acquisitions	-7.10	-31	-57	-210	-27	-88	-48	-4.00	-14	-109	-4.20
Sale of Property, Plant & Equipment	-0.30	-	1.50	-	-	1.10	4.80	38	-	3.60	0.00
Divestitures	1.00	0.40	-	-	-	0.60	0.00	-	-	1.50	0.90
Other Investing Activities, net	-0.30	-7.40	-7.00	-12	-2.80	-3.50	-11	-8.60	-12	-9.00	5.90
Net Cash From Financing Activities	-20	-45	32	190	-7.30	48	30	-63	-84	59	-56
Net Cash From Continuing Financing Activities	-20	-45	32	190	-7.30	48	30	-63	-84	59	-56
Repayment of Debt	-79	-724	-122	-873	-139	-174	-123	-179	-159	-574	-194
Payment of Dividends	-34	-28	-39	-41	-37	-44	-61	-53	-53	-59	-58
Issuance of Debt	93	707	193	1,103	168	266	214	169	128	693	195

This table presents Surgery Partners' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	2,104	2,305	4,623	4,676	5,019	5,413	6,118	6,682	6,877	7,890	8,120
Total Current Assets	311	362	563	588	526	802	946	921	895	1,119	1,151
Cash & Equivalents	58	70	175	184	93	318	390	283	196	270	240
Accounts Receivable	178	221	288	308	327	382	430	456	496	579	602
Inventories, net	26	29	45	43	46	56	61	71	75	88	97
Prepaid Expenses	35	43	17	16	18	18	26	31	31	36	41
Other Current Assets	15	-	39	37	42	27	39	79	97	146	171
Plant, Property, & Equipment, net	185	0.00	0.00	426	523	0.00	0.00	877	969	1,088	1,153
Total Noncurrent Assets	1,609	1,943	4,060	3,662	3,970	4,612	5,172	4,885	5,013	5,682	5,816
Long-Term Investments	34	35	74	79	93	90	89	190	184	215	234
Goodwill	1,408	1,555	3,347	3,383	3,402	3,468	3,912	4,137	4,326	5,068	5,236
Other Noncurrent Operating Assets	19	16	49	37	329	882	1,013	423	359	353	346
Total Liabilities & Shareholders' Equity	2,104	2,305	4,623	4,676	5,019	5,413	6,118	6,682	6,877	7,890	8,120
Total Liabilities	1,623	1,800	2,656	2,892	3,320	3,790	3,818	3,399	3,515	4,255	4,593
Total Current Liabilities	181	187	303	349	398	557	537	493	523	624	616
Short-Term Debt	27	28	59	56	56	64	60	63	73	101	99
Accounts Payable	45	50	85	83	97	100	125	152	172	209	209
Current Employee Benefit Liabilities	26	29	50	55	54	65	77	69	74	60	65
Other Current Liabilities	82	80	110	155	191	217	210	210	204	254	243
Total Noncurrent Liabilities	1,442	1,613	2,353	2,542	2,921	3,233	3,281	2,906	2,992	3,630	3,977
Long-Term Debt	1,228	1,414	2,131	2,271	2,525	2,792	2,878	2,559	2,702	3,269	3,603
Noncurrent Deferred & Payable Income Tax Liabilities	120	122	-	-	-	-	-	-	0.00	39	53
Other Noncurrent Operating Liabilities	94	76	222	271	397	441	403	347	290	322	321
Redeemable Noncontrolling Interest	183	181	630	686	716	741	330	342	327	439	396
Total Equity & Noncontrolling Interests	298	325	1,337	1,099	983	882	1,970	2,941	3,035	3,196	3,131
Total Preferred & Common Equity	-4.03	9.68	655	405	297	116	1,089	1,998	1,987	1,790	1,713
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-4.03	9.68	655	405	297	116	1,089	1,998	1,987	1,790	1,713
Common Stock	317	321	696	674	663	608	1,623	2,479	2,499	2,522	2,542
Retained Earnings	-321	-311	-41	-247	-316	-432	-503	-557	-569	-737	-815
Accumulated Other Comprehensive Income / (Loss)	-	-	0.00	-22	-51	-61	-32	76	58	4.80	-14
Noncontrolling Interest	302	315	682	694	687	767	881	943	1,047	1,407	1,418

This table presents Surgery Partners' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	6,537	6,643	6,621	6,780	6,976	7,489	7,534	7,949	7,955	7,947	8,042
Total Current Assets	738	869	810	876	896	1,013	1,036	1,075	1,105	1,102	1,083
Cash & Equivalents	155	246	177	236	185	214	222	229	250	203	182
Accounts Receivable	422	453	450	463	494	523	543	571	563	579	603
Inventories, net	69	72	70	69	77	81	82	88	87	92	101
Prepaid Expenses	36	29	39	35	32	45	45	36	46	45	39
Other Current Assets	57	69	73	73	108	150	144	150	159	183	158
Plant, Property, & Equipment, net	0.00	0.00	0.00	940	983	1,006	1,005	1,151	1,180	1,164	1,135
Total Noncurrent Assets	5,798	5,774	5,810	4,964	5,097	5,470	5,494	5,724	5,670	5,680	5,825
Long-Term Investments	189	192	192	196	189	227	215	219	220	229	225
Goodwill	4,187	4,253	4,291	4,301	4,451	4,859	4,862	5,171	5,140	5,135	5,245
Other Noncurrent Operating Assets	1,320	1,237	1,221	362	370	303	339	334	310	316	354
Total Liabilities & Shareholders' Equity	6,537	6,643	6,621	6,780	6,976	7,489	7,534	7,949	7,955	7,947	8,042
Total Liabilities	4,092	3,355	3,310	3,461	3,614	3,870	3,986	4,363	4,376	4,394	4,561
Total Current Liabilities	624	475	459	501	523	552	575	569	573	586	582
Short-Term Debt	117	63	65	62	77	92	97	104	110	103	100
Accounts Payable	138	144	132	149	174	174	171	165	175	175	169
Current Employee Benefit Liabilities	69	68	64	82	69	63	65	67	59	70	77
Other Current Liabilities	292	200	198	208	204	222	242	234	229	239	236
Total Noncurrent Liabilities	3,468	2,880	2,851	2,960	3,091	3,318	3,411	3,793	3,803	3,808	3,979
Long-Term Debt	3,103	2,531	2,505	2,640	2,794	3,040	3,094	3,447	3,465	3,461	3,614
Noncurrent Deferred & Payable Income Tax Liabilities	-	-	-	-	-	-	-	39	37	43	52
Other Noncurrent Operating Liabilities	365	349	346	320	297	279	317	308	300	304	314
Redeemable Noncontrolling Interest	339	346	328	332	324	442	436	431	422	411	383
Total Equity & Noncontrolling Interests	2,105	2,943	2,983	2,987	3,038	3,176	3,112	3,156	3,157	3,142	3,098
Total Preferred & Common Equity	1,173	1,962	2,018	2,005	1,967	1,952	1,897	1,740	1,748	1,730	1,688
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	1,173	1,962	2,018	2,005	1,967	1,952	1,897	1,740	1,748	1,730	1,688
Common Stock	1,624	2,479	2,503	2,496	2,497	2,512	2,515	2,527	2,539	2,544	2,550
Retained Earnings	-534	-582	-563	-568	-582	-597	-629	-775	-778	-800	-851
Accumulated Other Comprehensive Income / (Loss)	83	65	79	77	52	37	11	-12	-13	-14	-11
Noncontrolling Interest	933	981	965	982	1,071	1,224	1,215	1,416	1,408	1,413	1,410

This table displays calculated financial ratios and metrics derived from Surgery Partners' official financial filings.

Metric	2014	2015	2016	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	129,341,779.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	129,341,779.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-0.60
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Net Operating Profit after Tax (NOPAT)	36	101	181	54	195	128	263	272	329	30	330
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	4.89%	5.66%	0.45%	4.82%
Earnings before Interest and Taxes (EBIT)	51	25	193	78	234	183	302	345	328	349	390
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	70	65	232	145	310	278	401	460	446	501	566
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-1,434	-74	-17	0.00	-51	150	-425	-399	3.23	-734	95
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,469	1,644	1,842	3,849	4,094	4,072	4,760	5,432	5,757	6,521	6,755
Increase / (Decrease) in Invested Capital	1,469	175	198	0.00	246	-22	688	672	326	764	235
Book Value per Share	($8.18)	($0.08)	$0.20	$8.28	$6.00	$2.29	$13.21	$22.21	$15.71	$14.08	$13.24
Tangible Book Value per Share	($50.09)	($30.43)	($32.86)	($62.03)	($63.69)	($67.32)	($34.77)	($24.25)	($18.92)	($26.15)	($27.24)
Total Capital	1,583	1,737	1,947	4,111	4,280	4,480	5,239	5,905	6,137	7,006	7,229
Total Debt	1,361	1,255	1,442	2,327	2,581	2,857	2,939	2,622	2,775	3,370	3,702
Total Long-Term Debt	1,339	1,228	1,414	2,271	2,525	2,792	2,878	2,559	2,702	3,269	3,603
Net Debt	1,253	1,163	1,337	2,064	2,395	2,449	2,460	2,149	2,395	2,885	3,228
Capital Expenditures (CapEx)	7.74	33	39	21	56	-16	52	68	63	88	32
Debt-free, Cash-free Net Working Capital (DFCFNWC)	74	99	133	110	91	-8.80	80	208	249	327	395
Debt-free Net Working Capital (DFNWC)	149	157	203	295	183	309	470	490	445	596	635
Net Working Capital (NWC)	127	130	175	239	127	245	409	428	372	495	535
Net Nonoperating Expense (NNE)	63	28	96	150	150	127	192	185	193	17	231
Net Nonoperating Obligations (NNO)	1,247	1,163	1,337	2,064	2,395	2,449	2,460	2,149	2,395	2,885	3,228
Total Depreciation and Amortization (D&A)	19	40	40	67	77	95	99	115	118	153	176
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.04	$0.20	($4.96)	($2.29)	($3.19)	($1.12)	($0.59)	($0.09)	($1.33)	($0.61)
Adjusted Weighted Average Basic Shares Outstanding	0.00	36.07M	48.02M	48.03M	49.29M	59.86M	72.43M	91.95M	125.61M	126.12M	127.21M
Adjusted Diluted Earnings per Share	$0.00	$0.04	$0.20	($4.96)	($2.29)	($3.19)	($1.12)	($0.59)	($0.09)	($1.33)	($0.61)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	37.46M	48.19M	48.03M	49.29M	59.86M	72.43M	91.95M	125.61M	126.12M	127.21M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	($2.29)	($3.19)	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	48.16M	48.63M	48.80M	48.28M	48.78M	89.36M	126.03M	126.61M	127.61M	129.42M
Normalized Net Operating Profit after Tax (NOPAT)	52	112	176	158	216	167	284	272	275	300	391
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-

This table displays calculated financial ratios and metrics derived from Surgery Partners' official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	129,341,779.00	129,419,836.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	129,341,779.00	129,419,836.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-0.12	-0.28
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	8.62%	4.00%	7.69%	14.16%	14.29%	17.54%	8.17%	8.41%	6.63%	-	4.50%
EBITDA Growth	7.31%	7.03%	36.95%	-1.97%	-0.36%	21.51%	-10.48%	27.09%	30.69%	-	6.21%
EBIT Growth	11.47%	7.64%	63.79%	-13.11%	-26.27%	25.35%	-18.55%	31.72%	73.56%	-	6.30%
NOPAT Growth	141.52%	35.92%	98.12%	-35.92%	-52.19%	-188.83%	-32.66%	58.33%	142.81%	-	6.30%
Net Income Growth	430.36%	100.43%	1,925.00%	-50.78%	-78.45%	-199.79%	-101.23%	58.10%	295.31%	-	-600.00%
EPS Growth	85.71%	0.00%	50.00%	-180.00%	-525.00%	0.00%	-200.00%	83.33%	28.00%	-	6.67%
Operating Cash Flow Growth	252.19%	769.44%	-45.37%	58.93%	-37.67%	77.96%	-85.26%	-1.81%	28.22%	-	95.00%
Free Cash Flow Firm Growth	80.47%	61.08%	20.35%	-130.69%	-249.67%	-257.92%	-125.38%	64.31%	56.72%	-	93.39%
Invested Capital Growth	5.05%	5.99%	7.60%	14.50%	12.78%	13.26%	14.18%	5.93%	6.04%	-	1.47%
Revenue Q/Q Growth	0.97%	9.09%	-2.45%	6.23%	1.09%	12.20%	-10.23%	6.47%	-0.57%	-	-8.37%
EBITDA Q/Q Growth	-8.61%	18.83%	-17.21%	9.02%	-7.11%	44.91%	-39.01%	54.79%	-4.47%	-	-38.68%
EBIT Q/Q Growth	-15.37%	22.76%	-25.05%	11.58%	-28.18%	108.70%	-51.30%	80.45%	-5.37%	-	-40.29%
NOPAT Q/Q Growth	-33.73%	20.14%	-28.39%	12.39%	-50.56%	-323.23%	154.28%	164.26%	-24.17%	-	-38.60%
Net Income Q/Q Growth	-48.53%	57.24%	-47.97%	16.87%	-77.46%	-828.13%	99.36%	15,066.67%	-43.65%	-	-107.24%
EPS Q/Q Growth	-126.67%	0.00%	0.00%	-20.00%	-108.33%	-244.00%	65.12%	93.33%	-800.00%	-	-154.55%
Operating Cash Flow Q/Q Growth	100.77%	-40.15%	-34.98%	103.44%	-21.26%	70.86%	-94.61%	1,255.00%	2.83%	-	-88.68%
Free Cash Flow Firm Q/Q Growth	38.39%	-21.40%	-48.25%	-108.04%	6.61%	-24.26%	6.65%	67.06%	-13.25%	-	67.37%
Invested Capital Q/Q Growth	1.41%	3.01%	1.77%	7.70%	-0.11%	3.45%	2.59%	-0.08%	0.00%	-	0.48%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	71.07%	104.43%	36.14%	38.55%	70.35%	11.23%	41.44%	45.51%	70.44%	-	69.49%
EBITDA Margin	16.54%	18.02%	15.29%	15.69%	14.42%	18.63%	12.65%	18.40%	17.68%	-	12.86%
Operating Margin	12.25%	13.79%	10.59%	11.13%	7.91%	14.70%	7.98%	13.52%	12.87%	-	8.11%
EBIT Margin	12.25%	13.79%	10.59%	11.13%	7.91%	14.70%	7.98%	13.52%	12.87%	-	8.11%
Profit (Net Income) Margin	4.41%	6.35%	3.39%	3.73%	0.83%	-5.39%	-0.04%	5.43%	3.08%	-	-0.26%
Tax Burden Percent	90.55%	88.61%	84.67%	85.29%	58.72%	-62.80%	100.00%	102.51%	82.14%	-	63.64%
Interest Burden Percent	39.71%	51.97%	37.76%	39.27%	17.90%	58.38%	-0.48%	39.21%	29.14%	-	-5.02%
Effective Tax Rate	9.45%	11.39%	15.33%	14.71%	41.28%	162.80%	0.00%	-2.51%	17.86%	-	0.00%
Return on Invested Capital (ROIC)	5.52%	5.99%	4.44%	4.64%	2.33%	-4.68%	2.82%	6.91%	5.35%	-	2.82%
ROIC Less NNEP Spread (ROIC-NNEP)	3.77%	4.09%	2.71%	2.84%	1.16%	-3.43%	1.27%	4.50%	3.26%	-	1.32%
Return on Net Nonoperating Assets (RNNOA)	3.37%	2.80%	1.90%	2.01%	0.85%	-2.59%	1.02%	3.63%	2.70%	-	1.19%
Return on Equity (ROE)	8.89%	8.79%	6.33%	6.65%	3.18%	-7.27%	3.84%	10.53%	8.05%	-	4.01%
Cash Return on Invested Capital (CROIC)	0.77%	0.06%	-1.21%	-8.41%	-7.44%	-11.96%	-13.79%	-5.56%	-4.88%	-	3.52%
Operating Return on Assets (OROA)	5.00%	5.58%	4.35%	4.56%	3.30%	6.20%	3.39%	5.67%	5.47%	-	3.39%
Return on Assets (ROA)	1.80%	2.57%	1.39%	1.53%	0.35%	-2.27%	-0.02%	2.28%	1.31%	-	-0.11%
Return on Common Equity (ROCE)	4.90%	5.27%	3.74%	3.81%	1.81%	-3.92%	2.05%	5.42%	4.11%	-	1.95%
Return on Equity Simple (ROE_SIMPLE)	5.58%	0.00%	8.05%	6.61%	5.58%	0.00%	-0.70%	0.00%	0.00%	-	0.00%
Net Operating Profit after Tax (NOPAT)	75	90	64	72	36	-80	43	115	87	75	46
NOPAT Margin	11.10%	12.22%	8.97%	9.49%	4.64%	-9.23%	5.58%	13.86%	10.57%	-	5.68%
Net Nonoperating Expense Percent (NNEP)	1.75%	1.90%	1.72%	1.80%	1.17%	-1.26%	1.56%	2.40%	2.09%	-	1.50%
Return On Investment Capital (ROIC_SIMPLE)	-	1.55%	-	-	-	-1.22%	0.65%	1.70%	1.29%	1.10%	0.68%
Cost of Revenue to Revenue	28.93%	-4.43%	63.86%	61.45%	29.65%	88.77%	58.56%	54.49%	29.56%	-	30.51%
SG&A Expenses to Revenue	48.81%	78.15%	16.14%	17.41%	48.00%	-14.17%	22.54%	23.43%	46.78%	-	51.75%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Operating Expenses to Revenue	58.82%	90.64%	25.55%	27.42%	62.45%	-3.47%	33.47%	31.99%	57.58%	-	61.38%
Earnings before Interest and Taxes (EBIT)	83	101	76	85	61	127	62	112	106	110	66
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	112	133	110	120	111	161	98	152	145	170	104
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.85	2.04	1.92	1.55	2.16	1.50	1.74	1.63	1.60	-	0.91
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Price to Revenue (P/Rev)	1.36	1.48	1.35	1.05	1.37	0.86	0.96	0.88	0.84	-	0.46
Price to Earnings (P/E)	0.00	0.00	6,288.82	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Earnings Yield	0.00%	0.00%	0.02%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.30	1.36	1.31	1.17	1.35	1.14	1.19	1.16	1.16	-	0.98
Enterprise Value to Revenue (EV/Rev)	2.68	2.85	2.74	2.55	2.85	2.38	2.52	2.40	2.35	-	1.99
Enterprise Value to EBITDA (EV/EBITDA)	16.65	17.52	16.11	15.59	17.99	14.80	16.29	14.90	13.89	-	11.62
Enterprise Value to EBIT (EV/EBIT)	22.71	23.83	21.43	21.41	26.32	21.28	23.84	21.53	19.02	-	16.88
Enterprise Value to NOPAT (EV/NOPAT)	23.44	23.78	22.21	24.46	31.25	250.40	0.00	629.20	121.21	-	19.81
Enterprise Value to Operating Cash Flow (EV/OCF)	30.55	26.60	29.48	25.39	33.84	24.73	30.07	29.50	27.38	-	23.72
Enterprise Value to Free Cash Flow (EV/FCFF)	173.84	2,420.75	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	27.99
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.81	0.83	0.85	0.87	0.90	0.93	0.99	1.00	1.00	-	1.07
Long-Term Debt to Equity	0.80	0.80	0.83	0.84	0.87	0.90	0.96	0.97	0.97	-	1.04
Financial Leverage	0.89	0.68	0.70	0.71	0.73	0.75	0.81	0.81	0.83	-	0.91
Leverage Ratio	2.31	2.04	2.05	2.04	2.08	2.11	2.15	2.15	2.18	-	2.26
Compound Leverage Factor	0.92	1.06	0.77	0.80	0.37	1.23	-0.01	0.84	0.64	-	-0.11
Debt to Total Capital	44.88%	45.22%	46.06%	46.40%	47.35%	48.11%	49.75%	49.97%	50.07%	-	51.62%
Short-Term Debt to Total Capital	1.03%	1.19%	1.24%	1.37%	1.44%	1.45%	1.46%	1.54%	1.45%	-	1.40%
Long-Term Debt to Total Capital	43.85%	44.02%	44.83%	45.03%	45.91%	46.66%	48.29%	48.44%	48.63%	-	50.22%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%
Noncontrolling Interests to Total Capital	21.83%	22.40%	22.37%	24.68%	24.51%	26.34%	25.87%	25.59%	25.62%	-	24.92%
Common Equity to Total Capital	33.29%	32.38%	31.56%	28.92%	28.14%	25.55%	24.38%	24.44%	24.30%	-	23.46%
Debt to EBITDA	6.18	6.22	6.04	6.62	6.75	6.72	7.25	6.85	6.40	-	6.50
Net Debt to EBITDA	5.19	5.37	5.25	5.69	5.83	5.75	6.33	5.94	5.63	-	5.78
Long-Term Debt to EBITDA	6.04	6.06	5.87	6.42	6.54	6.52	7.04	6.63	6.22	-	6.32
Debt to NOPAT	8.69	8.44	8.32	10.38	11.73	113.71	-103.55	288.98	55.89	-	11.07
Net Debt to NOPAT	7.30	7.29	7.23	8.92	10.12	97.35	-90.49	250.96	49.10	-	9.86
Long-Term Debt to NOPAT	8.49	8.22	8.09	10.07	11.37	110.29	-100.52	280.08	54.27	-	10.77
Altman Z-Score	1.03	1.09	1.01	0.85	1.00	0.77	0.78	0.79	0.77	-	0.57
Noncontrolling Interest Sharing Ratio	44.86%	40.02%	40.91%	42.70%	43.19%	46.02%	46.64%	48.58%	48.94%	-	51.49%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.75	1.71	1.71	1.83	1.80	1.79	1.89	1.93	1.88	-	1.86
Quick Ratio	1.39	1.32	1.30	1.34	1.33	1.36	1.40	1.42	1.34	-	1.35
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-194	-236	-349	-727	-679	-843	-787	-259	-294	-159	-52
Operating Cash Flow to CapEx	544.79%	316.16%	208.72%	307.81%	322.77%	525.47%	33.52%	0.00%	422.22%	-	73.13%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.41	0.40	0.41	0.41	0.42	0.42	0.43	0.42	0.42	-	0.42
Accounts Receivable Turnover	6.13	5.76	5.90	5.94	5.94	5.79	5.96	5.96	5.86	-	5.70
Inventory Turnover	22.67	10.83	27.32	30.50	30.90	23.50	23.24	22.60	19.11	-	7.64
Fixed Asset Turnover	0.00	2.97	0.00	0.00	3.07	3.03	2.97	2.96	3.03	-	2.93
Accounts Payable Turnover	10.89	4.91	12.76	15.10	14.64	10.10	11.31	10.89	9.64	-	4.32
Days Sales Outstanding (DSO)	59.50	63.38	61.86	61.48	61.48	63.03	61.25	61.26	62.29	-	64.08
Days Inventory Outstanding (DIO)	16.10	33.70	13.36	11.97	11.81	15.53	15.71	16.15	19.10	-	47.78
Days Payable Outstanding (DPO)	33.51	74.35	28.59	24.18	24.93	36.13	32.26	33.51	37.86	-	84.51
Cash Conversion Cycle (CCC)	42.09	22.73	46.62	49.27	48.36	42.43	44.70	43.90	43.53	-	27.35
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	5,589	5,757	5,859	6,310	6,303	6,521	6,689	6,684	6,684	6,755	6,788
Invested Capital Turnover	0.50	0.49	0.49	0.49	0.50	0.51	0.51	0.50	0.51	-	0.50
Increase / (Decrease) in Invested Capital	269	326	414	799	715	764	831	374	381	235	98
Enterprise Value (EV)	7,284	7,816	7,665	7,381	8,505	7,422	7,980	7,784	7,729	-	6,642
Market Capitalization	3,700	4,047	3,773	3,024	4,098	2,691	3,031	2,849	2,774	-	1,543
Book Value per Share	$15.85	$15.71	$15.62	$15.36	$14.92	$14.08	$13.64	$13.64	$13.49	$13.24	$13.04
Tangible Book Value per Share	($18.15)	($18.92)	($19.72)	($22.87)	($23.32)	($26.15)	($26.89)	($26.46)	($26.56)	($27.24)	($27.48)
Total Capital	6,021	6,137	6,233	6,751	6,740	7,006	7,137	7,154	7,117	7,229	7,195
Total Debt	2,702	2,775	2,871	3,132	3,192	3,370	3,551	3,575	3,564	3,702	3,714
Total Long-Term Debt	2,640	2,702	2,794	3,040	3,094	3,269	3,447	3,465	3,461	3,603	3,614
Net Debt	2,270	2,395	2,497	2,692	2,755	2,885	3,103	3,105	3,131	3,228	3,306
Capital Expenditures (CapEx)	19	20	20	27	20	21	18	-15	20	9.20	16
Debt-free, Cash-free Net Working Capital (DFCFNWC)	201	249	265	340	336	327	380	392	416	395	419
Debt-free Net Working Capital (DFNWC)	437	445	450	553	558	596	609	642	619	635	601
Net Working Capital (NWC)	375	372	373	461	461	495	505	532	516	535	501
Net Nonoperating Expense (NNE)	45	43	40	44	29	-33	44	70	62	46	48
Net Nonoperating Obligations (NNO)	2,270	2,395	2,497	2,692	2,755	2,885	3,103	3,105	3,131	3,228	3,306
Total Depreciation and Amortization (D&A)	29	31	34	35	50	34	36	40	40	60	39
Debt-free, Cash-free Net Working Capital to Revenue	7.40%	9.09%	9.47%	11.75%	11.26%	10.50%	11.97%	12.11%	12.65%	-	12.53%
Debt-free Net Working Capital to Revenue	16.09%	16.23%	16.09%	19.15%	18.69%	19.15%	19.20%	19.83%	18.83%	-	17.98%
Net Working Capital to Revenue	13.80%	13.56%	13.33%	15.95%	15.43%	15.89%	15.92%	16.44%	15.70%	-	14.98%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.04)	$0.00	($0.10)	($0.12)	($0.25)	($0.86)	($0.30)	($0.02)	($0.18)	($0.11)	($0.28)
Adjusted Weighted Average Basic Shares Outstanding	125.75M	125.61M	125.97M	126.13M	126.17M	126.12M	126.60M	126.98M	127.21M	127.21M	128.37M
Adjusted Diluted Earnings per Share	($0.04)	$0.00	($0.10)	($0.12)	($0.25)	($0.86)	($0.30)	($0.02)	($0.18)	($0.11)	($0.28)
Adjusted Weighted Average Diluted Shares Outstanding	125.75M	125.61M	125.97M	126.13M	126.17M	126.12M	126.60M	126.98M	127.21M	127.21M	128.37M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	126.49M	126.61M	127.09M	127.12M	127.11M	127.61M	128.16M	128.21M	129.34M	129.42M	130.79M
Normalized Net Operating Profit after Tax (NOPAT)	89	110	76	84	52	106	62	89	100	84	58
Normalized NOPAT Margin	13.14%	14.94%	10.57%	10.98%	6.75%	12.29%	8.01%	10.82%	12.17%	-	7.10%
Pre Tax Income Margin	4.87%	7.17%	4.00%	4.37%	1.41%	8.58%	-0.04%	5.30%	3.75%	-	-0.41%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	130.56%	101.92%	88.51%	109.45%	136.48%	1,287.20%	-1,507.44%	4,418.18%	903.00%	-	228.94%
Augmented Payout Ratio	130.56%	101.92%	88.51%	109.45%	136.48%	1,287.20%	-1,507.44%	4,418.18%	903.00%	-	228.94%

Financials Breakdown Chart

Key Financial Trends

Here are the key trends from Surgery Partners (NASDAQ: SGRY) quarterly statements over the last four years, focusing on the main drivers that retail investors care about.

Revenue growth: Operating revenue rose from about $620.6 million in 2022 (Q3) to about $885 million in 2025 (Q4), roughly a 40%+ increase over the period, signaling a solid top-line expansion.
Stable operating profitability: 2025 Q4 operating income was $110.2 million on $885 million revenue, implying an operating margin of about 12%–13% and a pattern of mid-teen margins across 2023–2025.
Improving cash generation from operations: Net cash from continuing operating activities reached about $103.4 million in Q4 2025, reflecting stronger cash generation relative to earlier years.
Asset and liability scale: As of Q4 2025, total assets were about $7.95 billion and total liabilities around $4.39 billion, indicating a large, asset-rich balance sheet with substantial but manageable leverage.
Leverage footprint: Long-term debt hovered around $3.4–3.5 billion across the period, underscoring a high but relatively stable leverage level.
Equity base: Total equity excluding noncontrolling interests was in the neighborhood of $1.7–$1.8 billion, providing a modest cushion relative to liabilities.
Earnings per share pressures: Net income attributable to common shareholders has been negative in several quarters, including -$15.0 million in Q4 2025, indicating ongoing losses to common shareholders.
Significant investing cash outflows: In Q4 2025 the company posted meaningful net cash use in investing activities (e.g., roughly -$126.1 million), driven by PPE purchases and acquisitions.
Financing activity volatility: Financing cash flows reflect debt repayments, issuances, and dividends, contributing to cash flow volatility and occasional sizable outflows.
Per-share earnings remain negative: Basic and diluted earnings per share were negative in multiple periods (for example, Q4 2025 Basic EPS and Diluted EPS were -$0.11), underscoring ongoing challenges in translating revenue and cash flow into per-share profitability.

05/14/26 10:08 PM ETAI Generated. May Contain Errors.

Surgery Partners Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Surgery Partners' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Surgery Partners' net income appears to be on an upward trend, with a most recent value of $98.90 million in 2025, falling from -$27.05 million in 2014. The previous period was $12.50 million in 2024. View Surgery Partners' forecast to see where analysts expect Surgery Partners to go next.

Surgery Partners' total operating income in 2025 was $389.50 million, based on the following breakdown:

Total Gross Profit: $2.34 billion
Total Operating Expenses: $1.95 billion

Over the last 10 years, Surgery Partners' total revenue changed from $403.29 million in 2014 to $3.31 billion in 2025, a change of 720.4%.

Surgery Partners' total liabilities were at $4.59 billion at the end of 2025, a 7.9% increase from 2024, and a 183.0% increase since 2015.

In the past 10 years, Surgery Partners' cash and equivalents has ranged from $57.93 million in 2015 to $389.90 million in 2021, and is currently $239.90 million as of their latest financial filing in 2025.

Over the last 10 years, Surgery Partners' book value per share changed from -8.18 in 2014 to 13.24 in 2025, a change of -262.0%.

Related Companies

Financial statements for NASDAQ:SGRY last updated on 5/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Surgery Partners (SGRY) Financials

Financials Breakdown Chart

Key Financial Trends

Surgery Partners Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Surgery Partners (SGRY) Financials

Annual Income Statements for Surgery Partners

Quarterly Income Statements for Surgery Partners

Annual Cash Flow Statements for Surgery Partners

Quarterly Cash Flow Statements for Surgery Partners

Annual Balance Sheets for Surgery Partners

Quarterly Balance Sheets for Surgery Partners

Annual Metrics And Ratios for Surgery Partners

Quarterly Metrics And Ratios for Surgery Partners

Financials Breakdown Chart

Key Financial Trends

Surgery Partners Financials - Frequently Asked Questions

When does Surgery Partners' fiscal year end?

How has Surgery Partners' net income changed over the last 10 years?

What is Surgery Partners' operating income?

How has Surgery Partners' revenue changed over the last 10 years?

How much debt does Surgery Partners have?

How much cash does Surgery Partners have?

How has Surgery Partners' book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools